Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Market Cap	$767.40M	P/E Ratio	N/A
52W High	$7.55	52W Low	$2.12
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	34.9%	52W Position	75.3%
Overall Score	51	Value Score	40
Quality Score	50	Technical Score	63

EPS Current Est	$-0.64	EPS Next Est	$-0.51
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AQST	$6.21	-1.74%	1.16M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AQST	$6.21	-1.7%	1.16M
3
4
5
6

AQST

AQST

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Aquestive Therapeutics Inc. Data in Excel

Get Aquestive Therapeutics Inc. Data in Excel